Cellectis

Cellectis EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Cellectis (ALCLS.PA) as of Oct 20, 2026 is -3.94. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -2.88 — a change of 36.52% (lower).

EV/EBITDA

-3.94

YoY

36.52%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Cellectis is 2025 -3.94 . EV/EBITDA (Enterprise Value to EBITDA) of Cellectis was 2024 -2.88 . It decreases by 36.52% lower compared to the previous year.

The Cellectis EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
1.59 USD
Jan 1, 2019
0.24 USD
Jan 1, 2020
-1.31 USD
Jan 1, 2021
-2.14 USD
Jan 1, 2022
-2.99 USD
Jan 1, 2023
-1.69 USD
Jan 1, 2024
-2.88 USD
Jan 1, 2025
-3.94 USD
The Cellectis EV/EBITDA history
YEAREV/EBITDAYoY
-3.94+36.52%
-2.88+70.54%
-1.69-43.53%
-2.99+40.13%
-2.14+62.65%
-1.31-639.64%
0.24-84.71%
1.59+975.48%
0.15+71.91%
0.09-95.48%
1.90-110.58%
-18.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

EV/EBITDA (Enterprise Value to EBITDA) of Cellectis is -3.94 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Cellectis changed from -2.88 to -3.94, representing a 36.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Cellectis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Cellectis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cellectis

All Key Metrics — Cellectis